Apr. 21 at 12:36 AM
$TCMD Q1 2026 Earnings Release is scheduled for May 4, after the market close. Last quarter, the company guided to 2026 full-year revenue of
$357-
$365M (8%–11% YOY growth).
New Medicare prior authorization requirements for pneumatic compression devices began on April 13, 2026. So that was an unknown. My husband just got his approval last week for the FlexTouch Plus System (following surgery for cancer that included lymph node removal). Physical therapy has not helped. Compression garments have not helped. This is a very effective system. Much better than the tedious hand-lymphatic massage. Hopefully, others get access as needed. It seems like it would significantly improve patient compliance.
Other company catalysts:
$TCMD acquired LymphTech in February. TCMD is expanding its product offerings into related areas, such as the AffloVest for bronchiectasis and Airi for venous insufficiency, leveraging its existing sales and reimbursement channels for growth.
